Goldman Sachs has taken a bearish stance on Bicara Therapeutics, downgrading the stock from Neutral to Sell and slashing its price target by a significant 60.0%. The new target of $8 represents a steep drop from the previous $20 target.
The downgrade comes with an implied downside of 17.8% from the stock's closing price of $9.73 on October 29. This move reflects a notable shift in sentiment from the investment bank regarding the company's prospects.
Investors and traders can explore more price target data and ratings for Bicara Therapeutics on the Forecasts tab, as well as track all previous and future analyst recommendations in the dedicated News Flow section.
The information provided is not a recommendation for personal investment decisions and does not constitute investment advice.